Live Feed

Retirement plan advisors can now access Nestimate’s Target-Date Fund IQ Analysis through PGIM, equipping fiduciaries with a plan-centric framework to evaluate Target Date Funds and lifetime income solutions Nestimate, the innovative investment due diligence platform, has announced that its Target-Date Fund IQ Analysis tool is now available through PGIM, giving retirement plan advisors access to an objective framework for evaluating target-date funds and lifetime income solutions. Through this collaboration, retirement plan advisors can reach out to their PGIM Defined Contribution (DC) Solutions representative to run Nestimate’s reporting, enabling them to work directly with their plan s

Multiple winners receive cash prizes during eight-week competition, with Season Champion earning $75,000 top prize LAS VEGAS, Nevada, Aug. 26, 2026 (GLOBE NEWSWIRE) -- High Roller Technologies, Inc. ("High Roller" or the "Company") (NYSE:ROLR), a publicly traded online gaming and prediction markets company, today announced the winners of the ROLR™ Free-To-Trade Prediction Challenge, which concluded August 12, 2026 following an eight-week competition that introduced participants to the ROLR prediction markets brand ahead of its planned commercial launch. Michael D. Franz, who competed under the ROLR username m3t64, emerged as the competition's Season Champion, earning the $75,000 Season C

424B3 - Enhanced Group Inc. (0001956439) (Filer)

Hong Kong, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Cre8 Enterprise Limited (NASDAQ:CRE) ("Cre8" or the "Company"), a Hong Kong-based integrated financial printing service provider, announced today that the number of customers it served and its project backlog each reached record levels as of June 30, 2026, primarily driven by a surge in regional capital markets activity. The number of customers reached a new record level of 550 as of June 30, 2026, an increase of 83, or 17.8%, from 467 as of December 31, 2025, an increase of 149, or 37.2%, from 401 as of December 31, 2024,  and an increase of 142, or 34.8%, from 408 as of June 30, 2025. More specifically, number of times of IPO filing submissio

424B3 - Enhanced Group Inc. (0001956439) (Filer)

8-K - ABERCROMBIE & FITCH CO /DE/ (0001018840) (Filer)

8-K - Enhanced Group Inc. (0001956439) (Filer)

6-K - Rail Vision Ltd. (0001743905) (Filer)

ROCHESTER, NEW YORK, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Syntec Optics Holdings, Inc. (NASDAQ:OPTX), a leading provider of deep tech for the defense, space, AI data centers, and other vibrant end-markets, today announced a new order to build specialized high-tech waveguides for space satellites. After working on it for the past six months, Syntec is now ramping up to build and ship the product every week.  Syntec is making advanced antenna feeds that let satellites talk using several different channels, all at the same time. Usually, satellites need a whole bunch of different antennas, but when you work with some of the best talent in the nation as a customer, it is all done in one. However

Revenues for the first half of 2026 exceeded $1.0 million, compared to $237,000 in the first half of 2025 ShuntingYard technology integrated into Railserve’s commercially launched YardGUARD system; successful field testing completed with Israel Railways Ra’anana, Israel, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Rail Vision Ltd. (NASDAQ:RVSN, FSE: C80)) ("Rail Vision" or the "Company"), an early commercialization stage technology company transforming railway safety through advanced AI-integrated sensing systems, today announced its financial results for the first half ended June 30, 2026. "The first half of 2026 marked a period of strong commercial momentum for Rail Vision," said David BenDavid

8-K - Priority Technology Holdings, Inc. (0001653558) (Filer)

424B5 - Wetour Robotics Ltd (0001941158) (Filer)

Coinbase One members will be eligible for a lender-funded closing cost credit of up to $10,000 – applicable to all of Better’s home-financing products, including standard mortgages, HELOCs, and refinancesBetter Mortgage (NASDAQ:BETR) and Coinbase (NASDAQ:COIN) today announced general availability for Better’s token-backed, conforming mortgage product. These first-of-its-kind mortgages will be originated and serviced by Better, powered by Coinbase, and designed in accordance with guidelines from Fannie Mae, making the first lien a standard, conforming mortgage.As part of this offering, if approved for a loan by Better, Coinbase One members will be eligible for a rebate equal to 1% of the mort

Webinar to Highlight Unmet Needs in Hypothyroidism, Market Opportunity, and Planned Phase 3 Program for XP-8121 Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced details for a dedicated Program Overview webinar for XP-8121, the Company’s Phase 3-ready, once-weekly subcutaneous levothyroxine injection in development for the treatment of hypothyroidism. The XP-8121 webinar will take place on Wednesday, September 9, 2026, at 10 a.m. ET and will feature a leading endocrinologist, alongside members of the Xeris program te

- The ASCEND-ATTR study builds on the Phase 3 ATTRibute-CM CMR substudy results previously shared here, which indicated treatment with acoramidis may improve cardiac structure and function with evidence of amyloid regression in a subset of patients - ATTR-CM has long been treated as a disease where progression can be slowed, but these findings raise the possibility that acoramidis may be capable of reversing progression and actively restoring heart health. TTR stabilization with acoramidis may allow the body's natural amyloid clearance mechanisms to outpace amyloid formation, thereby enabling cardiac remodeling and functional recovery - ASCEND-ATTR will determine whether long-term acoramid

MILLBRAE, Calif., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (NASDAQ:EIKN) ("Eikon"), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced that Roger M. Perlmutter, M.D., Ph.D., Chairman and Chief Executive Officer, and Freddie Bowie, Ph.D., Chief Financial Officer, will participate in two upcoming investor conferences taking place in September: Event:12th Annual Cantor Global Healthcare Conference Location: New York, NYDate & Time: September 10, 2026 at 2:10 pm ETFormat: Fireside Chat Event: The Morgan Stanley 24th Annual Global Healthcare ConferenceLocation: New York, NYDate

Record second quarter net sales of $1.3 billion, up 5% to last year, 15th consecutive quarter of growthNet sales growth across regions with Americas up 5%, APAC up 19%, and EMEA up 2%Best-ever second quarter sales across brands, led by Abercrombie brands up 8%, with Hollister up 2%Operating margin of 20%, and earnings per diluted share of $4.17, both above outlook in excess of IEEPA tariff refund benefit of approximately $100 million on a pre-tax basis and $1.75 per diluted share; impact presented in table below$177 million in shares repurchased in the quarter; year-to-date share repurchases of $282 million totaling 7% of shares outstanding at beginning of the yearUpdates full-year outlook t

Professor Marlies Wijsenbeek will give an oral presentation on the quality-of-life outcomes assessed by the LCQ from the Phase 2b CORAL trial of nalbuphine ER for the treatment of patients with IPF-related chronic cough Dr. Imran Satia will give a poster presentation on the quality-of-life outcomes assessed by the LCQ from the Phase 2a RIVER trial of nalbuphine ER for the treatment of patients with RCC NEW HAVEN, Conn., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy oral nalbuphine ER for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF

WALTHAM, Mass., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will participate in the Wells Fargo 21st Annual Healthcare Conference in Boston, MA. Olivier Loeillot, President and Chief Executive Officer and Jason Garland, Chief Financial Officer, will participate in an analyst-led discussion on September 9th at 1:30 p.m. ET. A live webcast of the conference presentation will be accessible through Repligen’s Investor Relations website at www.repligen.com, and will be available for replay for a limited period of time following the event. About Repligen Corporation Repli

PHILADELPHIA, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Brandywine Realty Trust (NYSE:BDN) announced today the expiration of the previously announced cash tender offer (the "2029 Notes Tender Offer") by its operating partnership, Brandywine Operating Partnership, LP (the "Operating Partnership"), for up to $70,000,000 in aggregate principal amount (the "2029 Series Cap") of its outstanding 8.875% guaranteed notes due 2029 (the "2029 Notes"). The Operating Partnership previously announced that it had extended the 2029 Notes Tender Offer for the 2029 Notes. The 2029 Notes Tender Offer expired at 5:00 p.m., New York City time, on Tuesday, August 25, 2026 (the "2029 Notes Expiration Date") pursuant to